間葉幹細胞對於腫瘤的治療有效嗎?

標題:

      The role of mesenchymal stem cells in cancer development.

作者: Hiroshi Yagi^* and Yuko Kitagawa

·         Department of Surgery, School of Medicine, Keio University, Tokyo, Japan

·         出版期刊:  Frontiers in Genetics. ,4,p261.

·         出版年:  2013.

·         Doi: 10.3389/fgene.2013.00261

摘要:

The role of mesenchymal stem cells (MSCs) in cancer development is still controversial. MSCs may promote tumor progression through immune modulation, but other tumor suppressive effects of MSCs have also beendescribed. The discrepancy between these results may arise from issues related to different tissue sources, individual donor variability, and injection timing of MSCs. The expression of critical receptors such as Toll-like receptor is variable a teach time point of treatment, which may also determine the effects of MSCs on tumor progression. However, factors released from malignant cells, as well as surrounding tissues and the vasculature, are still regarded as a “black box. ” Thus, it is still difficult to clarify the specific role of MSCs in cancer development. Whether MSCs support or suppress tumor progression is currently unclear, but it is clear that systemically administered MSCs can be recruited and migrate toward tumors. These findings are important because they can be used as a basis for initiating studies to explore the incorporation of engineered MSCs as novel anti-tumor carriers, for the development of tumor-targeted therapies.

譯文:

      間葉幹細胞 ( MSCs ) 對於癌症發展目前仍有爭議. 間葉幹細胞可能會透過免疫調節方式促進或抑制腫瘤的進展.文獻報告的不一致可能的原因有不同組織來源,捐贈者個體的變異及注射間葉幹細胞的時間點.有些重要受器( Receptors )的表現如 Toll-like 受器在治療的時間點上是有變異的,亦會決定間葉幹細胞對腫瘤的影響.然而,從腫瘤細胞及周遭組織及血管所釋放出的物質仍然是個謎.因此很難去釐清間葉幹細胞在癌症發育的專一角色.

      間葉幹細胞是促進或是抑制腫瘤發展目前仍然不清楚,但是清楚的是有系統地注射的間葉幹細胞會聚集及移動到腫瘤處.這些發現相當重要因為間葉幹細胞可做為未來新奇抗腫瘤攜帶者的角色及腫瘤標靶治療的基礎.